BeOne Medicines

Company in Cambridge, Massachusetts, USA.

Texto en inglés

BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.

Último precio

—

Precio mínimo

—

Mediana 7 d

—

Ventas 30 d

Rango 30 d

—

En circulación

Cotización

Ver tabla

Fecha	mediana	Mín	Máx	ventas

Historial de ventas

Última venta: —
Media 30 d: —
Mínimo 30 d: —
Máximo 30 d: —
Ventas 7 d: 0
Ventas 30 d: 0

Aún no hay ventas.

Ventas anónimas: sin comprador ni vendedor. Las cifras solo cuentan ventas entre jugadores.

En Wikipedia

Texto en inglés Aún no hay artículo en tu idioma: extracto en inglés.

BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market. BeOne Medicines has developed several medicines, including tislelizumab (brand name of Tevimbra), a checkpoint inhibitor, and zanubrutinib (brand name of Brukinsa), a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025.

Texto: Wikipedia en inglés, CC BY-SA 4.0. ·